Intracellular Th

Company Profile

Intracellular Th had its IPO on 2014-01-07 under the ticker symbol ITCI.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Intracellular Th has a staff strength of 561 employees.

Stock update

Shares of Intracellular Th opened at $58.96 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $58.2 - $59.73, and closed at $59.31.

This is a +1.07% increase from the previous day's closing price.

A total volume of 499,100 shares were traded at the close of the day’s session.

In the last one week, shares of Intracellular Th have increased by +6.18%.

Intracellular Th's Key Ratios

Intracellular Th has a market cap of $5.69 billion, indicating a price to book ratio of 7.2913 and a price to sales ratio of 26.0933.

In the last 12-months Intracellular Th’s revenue was $365.84 million with a gross profit of $95.16 million and an EBITDA of $-198042000. The EBITDA ratio measures Intracellular Th's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Intracellular Th’s operating margin was -54.29% while its return on assets stood at -16.27% with a return of equity of -27.74%.

In Q2, Intracellular Th’s quarterly earnings growth was a positive 0% while revenue growth was a positive 99.3%.

Intracellular Th’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-1.97 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Intracellular Th’s profitability.

Intracellular Th stock is trading at a EV to sales ratio of 23.4771 and a EV to EBITDA ratio of -14.5751. Its price to sales ratio in the trailing 12-months stood at 26.0933.

Intracellular Th stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$713.60 million

Total Liabilities

$92.08 million

Operating Cash Flow

$94.75 million

Capital Expenditure

$0

Dividend Payout Ratio

0%

Intracellular Th ended 2024 with $713.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $713.60 million while shareholder equity stood at $607.09 million.

Intracellular Th ended 2024 with $0 in deferred long-term liabilities, $92.08 million in other current liabilities, 10000.00 in common stock, $-1564323000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $142.26 million and cash and short-term investments were $512.85 million. The company’s total short-term debt was $3,558,000 while long-term debt stood at $0.

Intracellular Th’s total current assets stands at $698.07 million while long-term investments were $0 and short-term investments were $370.60 million. Its net receivables were $95.96 million compared to accounts payable of $7.73 million and inventory worth $41.90 million.

In 2024, Intracellular Th's operating cash flow was $94.75 million while its capital expenditure stood at $0.

Comparatively, Intracellular Th paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$59.31

52-Week High

$67.05

52-Week Low

$42.01

Analyst Target Price

$78

Intracellular Th stock is currently trading at $59.31 per share. It touched a 52-week high of $67.05 and a 52-week low of $67.05. Analysts tracking the stock have a 12-month average target price of $78.

Its 50-day moving average was $59.29 and 200-day moving average was $55.94 The short ratio stood at 4.12 indicating a short percent outstanding of 0%.

Around 255.7% of the company’s stock are held by insiders while 9403.3% are held by institutions.